Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

Go online to PeerView.com/WUW860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Are you up to date on the practice-changing evidence
supporting the use of immunotherapy in resectable melanoma? In this
activity, a panel of surgical and medical oncology experts will
guide you through these new developments and provide insights on
the real-world use of immunotherapy in resectable melanoma,
including expanded applications of immunotherapy. The panelists
will tackle topics such as the use of checkpoint inhibitors as
standard adjuvant therapy in stage III/IV melanoma; the potential
of adjuvant immunotherapy in stage II disease; efficacy, safety,
and dosing information on neoadjuvant immunotherapy; and emerging
novel immune-based treatments in resectable melanoma (eg, LAG-3
inhibitors). This program will help inform the identification of
optimal candidates for immunotherapy, address treatment selection
and dosing considerations, and support effective management of
immune-related events. Upon completion of this CE activity,
participants will be able to: Summarize updated evidence and
guideline recommendations supporting the use of adjuvant and
neoadjuvant immunotherapy in resectable or potentially resectable
melanoma, including in stage II, III, and IV settings, Select
appropriate adjuvant immunotherapy options for patients with
resected melanoma requiring additional treatment, including those
with BRAF-mutant and wild-type disease, Integrate neoadjuvant
immunotherapy into the management of patients with melanoma who may
benefit from presurgical treatment, Manage immune-related adverse
events in patients with melanoma receiving immunotherapy in
conjunction with surgery.